Last 11 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.53 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.28 | 1.68 | 0.95 | 2.69 | 2.36 | 2.14 | 1.08 | — | — | — | — | — |
| — | -21.5% | -12.5% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -221.5% | -17.8% | -22.3% | -15.4% | -12.6% | -10.0% | -19.4% | — | — | — | — | — |
| — | -78.0% | -15.0% | — | — | — | — | — | — | — | — | — | |
| ROA | -59.2% | -16.0% | -20.0% | -14.1% | -11.6% | -9.4% | -7.9% | -10.9% | -4.9% | -6.2% | — | -19.4% |
| — | -69.4% | -152.0% | -29.1% | -137.6% | -51.0% | — | +43.8% | — | — | — | — | |
| ROIC | — | -85.3% | -39.7% | -19.5% | -13.6% | -10.1% | -167.0% | — | — | — | — | — |
| — | -749.0% | +76.2% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| — | +92.1% | -19.8% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.61 | 12.63 | 8.06 | 10.61 | 12.03 | 14.04 | 25.86 | 15.05 | 31.65 | 32.67 | — | 7.50 |
| — | -10.1% | -68.8% | -29.5% | -62.0% | -57.0% | — | +100.6% | — | — | — | — | |
| Quick Ratio | 10.61 | 12.63 | 8.06 | 10.61 | 12.03 | 14.04 | 25.86 | 15.05 | 31.65 | 32.67 | — | 7.50 |
| — | -10.1% | -68.8% | -29.5% | -62.0% | -57.0% | — | +100.6% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AARD stock.
Aardvark Therapeutics, Inc. Common Stock's current P/E is -0.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aardvark Therapeutics, Inc. Common Stock's business trajectory between earnings reports.